Tillotts Laboratories

Tillotts Pharma is a specialty pharmaceutical company dedicated to the development and commercialization of innovative pharmaceutical products in the field of gastroenterology. Headquartered in Switzerland and a subsidiary of Zeria Pharmaceutical, the company focuses on treatments for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. Their core portfolio includes established brands such as Asacol and Entocort, alongside a pipeline of targeted GI therapies. Tillotts utilizes proprietary drug delivery technologies like Medusa to optimize the release of active ingredients in the gastrointestinal tract. The company maintains a strong presence in Europe and continues to expand its global footprint through strategic acquisitions and partnerships.